Comorbidity in rheumatoid arthritis

Area of Science:

• Rheumatology
• Internal Medicine
• Clinical Research

Background:

• Coexisting diseases (comorbidities) significantly influence rheumatoid arthritis (RA) outcomes, including disability and mortality.
• RA-associated healthcare costs are rising rapidly, with comorbidities being a major cost driver.
• Current preventative measures for RA comorbidities are largely unproven and require rigorous investigation.

Purpose of the Study:

• To highlight the pivotal role of comorbidities in RA outcome.
• To emphasize the need for comprehensive RA management that addresses disease-specific comorbidities.
• To review recent advances in RA treatment and their potential impact on comorbidities.

Main Methods:

• Review of current understanding of RA comorbidities and their pathogenesis.
• Discussion of recent therapeutic advances in RA management, including DMARD combinations and new disease-modifying agents.
• Emphasis on the need for prospective, randomized investigations of preventative measures for RA comorbidities.

Main Results:

• Comorbidity independently predicts disability and mortality in RA patients.
• Advances in understanding RA pathogenesis are leading to new therapeutic interventions.
• New RA treatments like DMARD combinations, etanercept, and infliximab offer improved efficacy.

Conclusions:

• Addressing RA comorbidities is essential for improving patient quality of life and survival.
• Further research is needed to validate preventative strategies for RA comorbidities.
• The next decade holds promise for significant advancements in RA management through better comorbidity understanding and treatment.